SI1427817T1 - Razmnoževanje virusov in celičnih kultur - Google Patents

Razmnoževanje virusov in celičnih kultur

Info

Publication number
SI1427817T1
SI1427817T1 SI200230909T SI200230909T SI1427817T1 SI 1427817 T1 SI1427817 T1 SI 1427817T1 SI 200230909 T SI200230909 T SI 200230909T SI 200230909 T SI200230909 T SI 200230909T SI 1427817 T1 SI1427817 T1 SI 1427817T1
Authority
SI
Slovenia
Prior art keywords
viruses
multiplication
cell culture
cells
concerns
Prior art date
Application number
SI200230909T
Other languages
English (en)
Slovenian (sl)
Inventor
Jurgen Vorlop
Christian Frech
Holger Lubben
Jens-Peter Gregersen
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of SI1427817T1 publication Critical patent/SI1427817T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12051Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200230909T 2001-09-12 2002-09-11 Razmnoževanje virusov in celičnih kultur SI1427817T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
EP02777068A EP1427817B1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur
PCT/EP2002/010207 WO2003023025A1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Publications (1)

Publication Number Publication Date
SI1427817T1 true SI1427817T1 (sl) 2010-08-31

Family

ID=7698761

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230909T SI1427817T1 (sl) 2001-09-12 2002-09-11 Razmnoževanje virusov in celičnih kultur

Country Status (16)

Country Link
US (1) US20050118698A1 (https=)
EP (1) EP1427817B1 (https=)
JP (2) JP2005502357A (https=)
KR (1) KR100968141B1 (https=)
AT (1) ATE466932T1 (https=)
AU (1) AU2002338666B2 (https=)
BR (1) BR0212469A (https=)
CA (1) CA2456561A1 (https=)
CY (1) CY1110716T1 (https=)
DE (2) DE10144903A1 (https=)
DK (1) DK1427817T3 (https=)
ES (1) ES2345606T3 (https=)
NZ (1) NZ532203A (https=)
PT (1) PT1427817E (https=)
SI (1) SI1427817T1 (https=)
WO (1) WO2003023025A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537760A (ja) * 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) * 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2344634A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2778332A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
SG192821A1 (en) * 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
WO2014031480A1 (en) * 2012-08-24 2014-02-27 Xcellerex, Inc. Virus purification and formulation process
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
KR19990072201A (ko) * 1996-10-18 1999-09-27 무타이 마사히꼬 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
KR100797547B1 (ko) * 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법

Also Published As

Publication number Publication date
HK1062029A1 (zh) 2004-10-15
DK1427817T3 (da) 2010-08-23
CY1110716T1 (el) 2015-06-10
DE10144903A1 (de) 2003-03-27
ES2345606T3 (es) 2010-09-28
BR0212469A (pt) 2004-08-24
ATE466932T1 (de) 2010-05-15
PT1427817E (pt) 2010-08-10
US20050118698A1 (en) 2005-06-02
AU2002338666B2 (en) 2008-11-20
JP2005502357A (ja) 2005-01-27
KR100968141B1 (ko) 2010-07-06
CA2456561A1 (en) 2003-03-20
EP1427817B1 (de) 2010-05-05
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
KR20050027164A (ko) 2005-03-17
NZ532203A (en) 2005-04-29
EP1427817A1 (de) 2004-06-16
JP2010246559A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
SI1427817T1 (sl) Razmnoževanje virusov in celičnih kultur
WO2003023021A3 (de) Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
DE60037450D1 (de) Funf-helix protein
UA85536C2 (en) Viral antigens
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
DE60132443D1 (de) In lebenden zielzellen
WO2005092924A3 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
SI1517987T1 (sl) Pljučne celice bombaževih podgan za kulturo virusa
WO2004031209A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
SG159525A1 (en) Vaccine
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
WO2007002172A3 (en) Hiv-1 protease inhibitors
EP1309342A4 (en) PREPARATION OF A CHIMERIC PAPILLOMA VIRUS (22.01.2)
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
JOHANRLILLEHAUG RNA splicing and SR protein phosphorylation under stress in acute myeloid leukemia (AML)
TW200621800A (en) Human immunodeficiency virus vaccine
EA200101228A1 (ru) ИСПОЛЬЗОВАНИЕ АНТИТЕЛ, УЗНАЮЩИХ РЕЦЕПТОР ИНТЕРЛЕЙКИН-2, ДЛЯ ПРЕДУПРЕЖДЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСАМИ СПИДа
UA67251A (en) Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums
AU2002224974A1 (en) Method for increasing the virus propagation and the virus yield in cell cultures by blocking the activation of rnasel